Evidence map›Paper›PMID 37728700›Full record

ArticleJournal of cancer research and clinical oncology2023

MicroRNA biomarkers and their use in evaluating the prognosis of lung cancer.

Ruijie Wu, Bohan Zhang, Mengju He, Yani Kang, Gong Zhang

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ruijie WuDepartment of Radiotherapy, Fifth Clinical Medical College of ShanXi Medical University, No. 29 Shuangta East Street, Yingze District, Taiyuan, 030000, Shanxi, China.
Bohan ZhangSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China.
Mengju HeSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China.
Yani KangSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China.
Gong ZhangDepartment of Radiotherapy, Fifth Clinical Medical College of ShanXi Medical University, No. 29 Shuangta East Street, Yingze District, Taiyuan, 030000, Shanxi, China. gongzhang19820703@126.com.
Shanghai Jiao Tong University · CNShanxi Medical University · CN

Funding

Biomedical Data Translator Technical Feasibility Assessment and Architecture DesignOT3TR002020 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI AHALT, STANLEY CARLTON, TROPSHA, ALEXANDER · 2016 to 2019
$3.1M
Interdisciplinary Program of Medical Engineering Cross Fund YG2019GD02, YG2019QNB23 and YG2019QNA52National Infrastructures for Translational Medicine TMSK-2020-109Natural Science Foundation of Shanghai 19ZR1476100Outstanding Youths Project of Shanxi Science and Technology Department 201901D211524
6 · The paper itself

Abstract

objectiveWe aim to use the microRNA (miRNA, micro-ribonucleic acid) data of lung cancer tissues to establish a miRNA biomarker database for lung cancer that can be used for marker screening and analysis of lung cancer prognosis.

methodsWe obtained lung cancer-related data from The Cancer Genome Atlas (TCGA) and analyzed the miRNA expression profiles of lung cancer tissues and normal tissues using bioinformatics techniques to develop a new composite miRNA-based model for the prognostic assessment of lung cancer. The predictive power of this model was verified and evaluated based on grouping of data. We also performed RT-qPCR using lung cancer tissues from patients diagnosed with lung cancer.

resultsThere was a significant difference between the miRNA expression profiles of lung cancer tissues and normal tissues adjacent to the cancerous lesions. The prognostic survival of patients with lung cancer was closely related to onset age and staging (p = 0.012) but was not related to gender (p = 0.39) and race (p = 0.51). Using three methods of survival model construction, we identified three miRNA composites, namely hsa-mir-21, hsa-mir-141, and has-mir-490, as markers for the prognosis of lung cancer. As confirmed by RT-qPCR, the expressions of hsa-miR-21-5p and hsa-miR-141-5p were upregulated, whereas hsa-miR-490-3p expression was downregulated in lung cancer lesion tissues.

conclusionThe three miRNA composites identified, namely hsa-mir-21, hsa-mir-141, and hsa-mir-490, have the potential to serve as novel prognostic biomarkers and therapeutic targets for lung cancer.

Indexed as

Lung NeoplasmsMicroRNAsBiomarkers, TumorHumansPrognosisBiomarkers, TumorMicroRNAsBiomarkersLung cancermiRNASurvival analysis

Identifiers

PMID37728700
PMCPMC11798308
OpenAlexW4386878020

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.